Stocks · Health care · Pharmaceutical Preparations

Clene Inc.

CLNN Clue Score16
United States Fiscal year ends December CIK 0001822791 Results filed 4 Nov 2026

What the insiders did Net buying

By person

11 insiders · 136 transactions
1.0×

Robert Etherington holds only 1.0 times base salary in stock. $510.13K of shares against $508.76K in salary for 2025.

Salary from the company's own proxy. The shares are what Robert Etherington last reported holding, valued at $6.20, the price Common Stock was last bought or sold at on the open market here, on 12 May 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
David J Matlin
Director
$9.87M (29)
—
+$9.87M
1,069,775
$6.63M
—
Alison Mosca
Director
$3.23M (4)
—
+$3.23M
984,474
$6.10M
—
Chidozie Ugwumba
10% owner
$7.00M (2)
$5.78M (62)
+$1.22M
103,417
$641.19K
—
General Resonance LLC entity
10% owner
—
$1.16M (18)
−$1.16M
704,591
$4.37M
−40.7%
Jonathon Gay
Director
$1.11M (3)
—
+$1.11M
1,339,119
$8.30M
+501.5%
John Henry Stevens
Director
$586.66K (3)
—
+$586.66K
908,857
$5.63M
+736.5%
Mark Mortenson
Chief Science Officer
$97.43K (1)
$50.01K (1)
+$47.42K
28,949
$179.48K
—
Robert Dee Etherington
President & CEO
$67.75K (2)
$110.84K (1)
−$43.09K
82,279
$510.13K
—
Robert Glanzman
Chief Medical Officer
—
$9.58K (1)
−$9.58K
10,564
$65.50K
—
Reed N Wilcox
Director
—
—
—
575,145
$3.57M
+2,857%
Shalom Jacobovitz
Director
—
—
—
54,207
$336.08K
+62.4%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.